Ardelyx

Commercial-stage biopharma with two FDA-approved oral, gut-restricted small molecules: IBSRELA (tenapanor) for IBS with constipation and XPHOZAH (tenapanor) for hyperphosphatemia in adults on dialysis. Both are first-in-class NHE3 inhibitors and are being scaled in the U.S. with a focused commercial organization.